Study of rise in cases of mucormycosis during covid-19 pandemic

---

Original Article

Author Details : Subhadra Tissopi, Vishakha Shikhare, Meena Ramteerthakar, Pankaj A Joshi*, Vanita A Kulkarni

Volume : 8, Issue : 1, Year : 2022

Article Page : 55-58

https://doi.org/10.18231/j.ijmmtd.2022.012

Suggest article by email

Get Permission

---

Abstract

Background and Aims: There are reports of the rise of Rhino-orbital mucormycosis in COVID-19 patients during the second wave of the COVID-19 pandemic in India. Mucormycosis developed in patients who had the history of COVID-19 infection, uncontrolled diabetes mellitus with associated co-morbidities like hypertension, bilateral pneumonia, ischemic heart disease and concurrent use of steroids and oxygen therapy. So, to understand the association of mucormycosis with COVID-19 and other co-morbidities, we conducted a systemic study of mucormycosis in people with COVID-19.
Materials and Methods: Tissue samples of patients, clinically and radiologically suspected of mucormycosis, received in microbiology department were examined by KOH mount microscopically and cultured on SDA. The culture isolates were then subjected to lactophenol cotton blue for identification.
Results and Observations: A total of 35(72.91%) samples were positive for fungal filaments in either KOH mount or fungal growth on SDA. spp. was most commonly isolated in culture, followed by spp. Mucormycosis was predominantly seen in males, 37(77.08%), than in females, 11(22.91%). The commonest risk factors associated with mucormycosis were COVID-19 positivity 42(87.5%) and diabetes mellitus 41(85.41%).
Conclusion: To reduce the risk of fungal infection, all efforts should be made to maintain blood glucose levels under control and judicious use of corticosteroids in patients with COVID-19.
 

Keywords: COVID­19, Rhino­orbital mucormycosis, Diabetes mellitus, Corticosteroids

How to cite : Tissopi S, Shikhare V, Ramteerthakar M, Joshi P A, Kulkarni V A, Study of rise in cases of mucormycosis during covid-19 pandemic. IP Int J Med Microbiol Trop Dis 2022;8(1):55-58

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.